Despite ongoing challenges, GM-CSF+ Th cells are increasingly recognized as central amplifiers of inflammation and autoimmunity in T1D, offering a new immunological axis for therapeutic innovation. Here, CSF2 is linked to type 1 diabetes mellitus.